Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 96

1.

Phase 2 study of LY3023414 in patients with advanced endometrial cancer harboring activating mutations in the PI3K pathway.

Rubinstein MM, Hyman DM, Caird I, Won H, Soldan K, Seier K, Iasonos A, Tew WP, O'Cearbhaill RE, Grisham RN, Hensley ML, Troso-Sandoval T, Sabbatini P, Guillen J, Selcuklu SD, Zimel C, Torrisi J, Aghajanian C, Makker V.

Cancer. 2019 Dec 27. doi: 10.1002/cncr.32677. [Epub ahead of print]

PMID:
31880826
3.

Response to Berlaimont and Welby.

Checchi M, Mesher D, Mohammed H, Soldan K.

Sex Transm Infect. 2019 Nov;95(7):553. doi: 10.1136/sextrans-2019-054148. Epub 2019 Jul 18. No abstract available.

PMID:
31320395
4.

HPV vaccination of gay, bisexual and other men who have sex with men in sexual health and HIV clinics in England: vaccination uptake and attendances during the pilot phase.

Checchi M, Mesher D, McCall M, Coukan F, Chau C, Mohammed H, Duffell S, Edelstein M, Yarwood J, Soldan K.

Sex Transm Infect. 2019 Dec;95(8):608-613. doi: 10.1136/sextrans-2018-053923. Epub 2019 Apr 26.

PMID:
31028226
5.

Clinical impact and cost-effectiveness of primary cytology versus human papillomavirus testing for cervical cancer screening in England.

Bains I, Choi YH, Soldan K, Jit M.

Int J Gynecol Cancer. 2019 Apr 24. pii: ijgc-2018-000161. doi: 10.1136/ijgc-2018-000161. [Epub ahead of print]

6.

Correction: Sera selected from national STI surveillance system shows Chlamydia trachomatis PgP3 antibody correlates with time since infection and number of previous infections.

Blomquist PB, Migchelsen SJ, Wills G, McClure E, Ades AE, Kounali D, Dunbar JK, McClure MO, Soldan K, Woodhall SC, Horner P.

PLoS One. 2019 Apr 24;14(4):e0216193. doi: 10.1371/journal.pone.0216193. eCollection 2019.

7.

Has Chlamydia trachomatis prevalence in young women in England, Scotland and Wales changed? Evidence from national probability surveys.

Kounali DZ, Welton NJ, Soldan K, Woodhall SC, Dunbar JK, Migchelsen SJ, Mercer CH, Horner P, Ades AE.

Epidemiol Infect. 2019 Jan;147:e107. doi: 10.1017/S0950268819000347.

8.

Implementation and evaluation of the human papillomavirus (HPV) vaccination pilot for men who have sex with men (MSM), England, April 2016 to March 2017.

Edelstein M, Iyanger N, Hennessy N, Mesher D, Checchi M, Soldan K, McCall M, Nugent J, Crofts J, Lo J, Gilson R, Powell K, Ramsay M, Yarwood J.

Euro Surveill. 2019 Feb;24(8). doi: 10.2807/1560-7917.ES.2019.24.8.1800055.

9.

Declines in anogenital warts diagnoses since the change in 2012 to use the quadrivalent HPV vaccine in England: data to end 2017.

Checchi M, Mesher D, Mohammed H, Soldan K.

Sex Transm Infect. 2019 Aug;95(5):368-373. doi: 10.1136/sextrans-2018-053751. Epub 2019 Feb 5.

PMID:
30723186
10.

Epidemiology of genital warts in the British population: implications for HPV vaccination programmes.

Sonnenberg P, Tanton C, Mesher D, King E, Beddows S, Field N, Mercer CH, Soldan K, Johnson AM.

Sex Transm Infect. 2019 Aug;95(5):386-390. doi: 10.1136/sextrans-2018-053786. Epub 2019 Feb 5.

11.

Sera selected from national STI surveillance system shows Chlamydia trachomatis PgP3 antibody correlates with time since infection and number of previous infections.

Blomquist PB, Mighelsen SJ, Wills G, McClure E, Ades AE, Kounali D, Dunbar JK, McClure MO, Soldan K, Woodhall SC, Horner P.

PLoS One. 2018 Dec 17;13(12):e0208652. doi: 10.1371/journal.pone.0208652. eCollection 2018. Erratum in: PLoS One. 2019 Apr 24;14(4):e0216193.

12.
13.

Estimating chlamydia prevalence: more difficult than modelling suggests.

Soldan K, Dunbar JK, Gill ON.

Lancet Public Health. 2018 Sep;3(9):e416. doi: 10.1016/S2468-2667(18)30166-X. No abstract available.

14.

The Impact of the National HPV Vaccination Program in England Using the Bivalent HPV Vaccine: Surveillance of Type-Specific HPV in Young Females, 2010-2016.

Mesher D, Panwar K, Thomas SL, Edmundson C, Choi YH, Beddows S, Soldan K.

J Infect Dis. 2018 Aug 14;218(6):911-921. doi: 10.1093/infdis/jiy249.

PMID:
29917082
15.

A Randomized Trial of Prophylactic Extended Carboplatin Infusion to Reduce Hypersensitivity Reactions in Recurrent Ovarian Cancer.

LaVigne K, Hyman DM, Zhou QC, Iasonos A, Tew WP, Aghajanian C, Makker V, Hensley ML, Konner J, Grisham RN, Cangemi N, Soldan K, Spriggs DR, Sabbatini PJ, OʼCearbhaill RE.

Int J Gynecol Cancer. 2018 Jul;28(6):1176-1182. doi: 10.1097/IGC.0000000000001280.

16.

Effect of HPV vaccination and cervical cancer screening in England by ethnicity: a modelling study.

Johnson HC, Lafferty EI, Eggo RM, Louie K, Soldan K, Waller J, Edmunds WJ.

Lancet Public Health. 2018 Jan;3(1):e44-e51. doi: 10.1016/S2468-2667(17)30238-4. Epub 2017 Dec 19.

17.

Human papillomavirus (HPV) in young women in Britain: Population-based evidence of the effectiveness of the bivalent immunisation programme and burden of quadrivalent and 9-valent vaccine types.

Tanton C, Mesher D, Beddows S, Soldan K, Clifton S, Panwar K, Field N, Mercer CH, Johnson AM, Sonnenberg P.

Papillomavirus Res. 2017 Jun;3:36-41. doi: 10.1016/j.pvr.2017.01.001.

18.

Development of an internally braced prosthesis for total talus replacement.

Regauer M, Lange M, Soldan K, Peyerl S, Baumbach S, Böcker W, Polzer H.

World J Orthop. 2017 Mar 18;8(3):221-228. doi: 10.5312/wjo.v8.i3.221. eCollection 2017 Mar 18.

19.

Attendance of MSM at Genitourinary Medicine services in England: implications for selective HPV vaccination programme (a short communication).

Bayley J, Mesher D, Nadarzynski T, Hughes G, Soldan K.

Sex Transm Infect. 2018 Nov;94(7):542-544. doi: 10.1136/sextrans-2016-052912. Epub 2017 Mar 9.

PMID:
28280237
20.

Filling in the gaps: estimating numbers of chlamydia tests and diagnoses by age group and sex before and during the implementation of the English National Screening Programme, 2000 to 2012.

Chandra NL, Soldan K, Dangerfield C, Sile B, Duffell S, Talebi A, Choi YH, Hughes G, Woodhall SC.

Euro Surveill. 2017 Feb 2;22(5). doi: 10.2807/1560-7917.ES.2017.22.5.30453.

21.

Chlamydia trachomatis Pgp3 Antibody Population Seroprevalence before and during an Era of Widespread Opportunistic Chlamydia Screening in England (1994-2012).

Woodhall SC, Wills GS, Horner PJ, Craig R, Mindell JS, Murphy G, McClure MO, Soldan K, Nardone A, Johnson AM.

PLoS One. 2017 Jan 27;12(1):e0152810. doi: 10.1371/journal.pone.0152810. eCollection 2017.

22.

Impact and Cost-effectiveness of Selective Human Papillomavirus Vaccination of Men Who Have Sex With Men.

Lin A, Ong KJ, Hobbelen P, King E, Mesher D, Edmunds WJ, Sonnenberg P, Gilson R, Bains I, Choi YH, Tanton C, Soldan K, Jit M.

Clin Infect Dis. 2017 Mar 1;64(5):580-588. doi: 10.1093/cid/ciw845.

23.

Population-Level Effects of Human Papillomavirus Vaccination Programs on Infections with Nonvaccine Genotypes.

Mesher D, Soldan K, Lehtinen M, Beddows S, Brisson M, Brotherton JM, Chow EP, Cummings T, Drolet M, Fairley CK, Garland SM, Kahn JA, Kavanagh K, Markowitz L, Pollock KG, Söderlund-Strand A, Sonnenberg P, Tabrizi SN, Tanton C, Unger E, Thomas SL.

Emerg Infect Dis. 2016 Oct;22(10):1732-40. doi: 10.3201/eid2210.160675. Review.

24.

Oral Human Papillomavirus Infection in Men Who Have Sex with Men: A Systematic Review and Meta-Analysis.

King EM, Oomeer S, Gilson R, Copas A, Beddows S, Soldan K, Jit M, Edmunds WJ, Sonnenberg P.

PLoS One. 2016 Jul 6;11(7):e0157976. doi: 10.1371/journal.pone.0157976. eCollection 2016. Review.

25.

Chlamydia sequelae cost estimates used in current economic evaluations: does one-size-fit-all?

Ong KJ, Soldan K, Jit M, Dunbar JK, Woodhall SC.

Sex Transm Infect. 2017 Feb;93(1):18-24. doi: 10.1136/sextrans-2016-052597. Epub 2016 Jun 9.

PMID:
27288417
26.

The natural history of Chlamydia trachomatis infection in women: a multi-parameter evidence synthesis.

Price MJ, Ades AE, Soldan K, Welton NJ, Macleod J, Simms I, DeAngelis D, Turner KM, Horner PJ.

Health Technol Assess. 2016 Mar;20(22):1-250. doi: 10.3310/hta20220. Review.

27.

HPV Serology Testing Confirms High HPV Immunisation Coverage in England.

Mesher D, Stanford E, White J, Findlow J, Warrington R, Das S, Pebody R, Borrow R, Soldan K.

PLoS One. 2016 Mar 9;11(3):e0150107. doi: 10.1371/journal.pone.0150107. eCollection 2016.

28.

Continuing reductions in HPV 16/18 in a population with high coverage of bivalent HPV vaccination in England: an ongoing cross-sectional study.

Mesher D, Panwar K, Thomas SL, Beddows S, Soldan K.

BMJ Open. 2016 Feb 11;6(2):e009915. doi: 10.1136/bmjopen-2015-009915.

29.

Epidemiology of Mycoplasma genitalium in British men and women aged 16–44 years: evidence from the third National Survey of Sexual Attitudes and Lifestyles (Natsal-3).

Sonnenberg P, Ison CA, Clifton S, Field N, Tanton C, Soldan K, Beddows S, Alexander S, Khanom R, Saunders P, Copas AJ, Wellings K, Mercer CH, Johnson AM.

Int J Epidemiol. 2015 Dec;44(6):1982-94. doi: 10.1093/ije/dyv194.

31.

Can we use postal surveys with anonymous testing to monitor chlamydia prevalence in young women in England? Pilot study incorporating randomised controlled trial of recruitment methods.

Woodhall SC, Nichols T, Alexander S, da Silva FC, Mercer CH, Ison C, Gill ON, Soldan K.

Sex Transm Infect. 2015 Sep;91(6):412-4. doi: 10.1136/sextrans-2015-052067.

PMID:
26294693
32.

Is chlamydia screening and testing in Britain reaching young adults at risk of infection? Findings from the third National Survey of Sexual Attitudes and Lifestyles (Natsal-3).

Woodhall SC, Soldan K, Sonnenberg P, Mercer CH, Clifton S, Saunders P, da Silva F, Alexander S, Wellings K, Tanton C, Field N, Copas AJ, Ison CA, Johnson AM.

Sex Transm Infect. 2016 May;92(3):218-27. doi: 10.1136/sextrans-2015-052013. Epub 2015 Aug 19.

33.

Oral human papillomavirus (HPV) infection in men who have sex with men: prevalence and lack of anogenital concordance.

King EM, Gilson R, Beddows S, Soldan K, Panwar K, Young C, Jit M, Edmunds WJ, Sonnenberg P.

Sex Transm Infect. 2015 Jun;91(4):284-6. doi: 10.1136/sextrans-2014-051955. Epub 2015 Apr 17.

34.

Human papillomavirus DNA in men who have sex with men: type-specific prevalence, risk factors and implications for vaccination strategies.

King EM, Gilson R, Beddows S, Soldan K, Panwar K, Young C, Prah P, Jit M, Edmunds WJ, Sonnenberg P.

Br J Cancer. 2015 Apr 28;112(9):1585-93. doi: 10.1038/bjc.2015.90. Epub 2015 Mar 19.

35.

Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis.

Drolet M, Bénard É, Boily MC, Ali H, Baandrup L, Bauer H, Beddows S, Brisson J, Brotherton JM, Cummings T, Donovan B, Fairley CK, Flagg EW, Johnson AM, Kahn JA, Kavanagh K, Kjaer SK, Kliewer EV, Lemieux-Mellouki P, Markowitz L, Mboup A, Mesher D, Niccolai L, Oliphant J, Pollock KG, Soldan K, Sonnenberg P, Tabrizi SN, Tanton C, Brisson M.

Lancet Infect Dis. 2015 May;15(5):565-80. doi: 10.1016/S1473-3099(14)71073-4. Epub 2015 Mar 3. Review.

36.

High-Risk Human Papillomavirus (HPV) Infection and Cervical Cancer Prevention in Britain: Evidence of Differential Uptake of Interventions from a Probability Survey.

Tanton C, Soldan K, Beddows S, Mercer CH, Waller J, Field N, Clifton S, Copas AJ, Panwar K, Manyenga P, da Silva F, Wellings K, Ison CA, Johnson AM, Sonnenberg P.

Cancer Epidemiol Biomarkers Prev. 2015 May;24(5):842-53. doi: 10.1158/1055-9965.EPI-14-1333. Epub 2015 Mar 3.

37.

Confirmatory assays are essential when using molecular testing for Neisseria gonorrhoeae in low-prevalence settings: insights from the third National Survey of Sexual Attitudes and Lifestyles (Natsal-3).

Field N, Clifton S, Alexander S, Ison CA, Hughes G, Beddows S, Tanton C, Soldan K, Coelho da Silva F, Mercer CH, Wellings K, Johnson AM, Sonnenberg P.

Sex Transm Infect. 2015 Aug;91(5):338-41. doi: 10.1136/sextrans-2014-051850. Epub 2014 Dec 15.

38.

Type-specific HPV prevalence in invasive cervical cancer in the UK prior to national HPV immunisation programme: baseline for monitoring the effects of immunisation.

Mesher D, Cuschieri K, Hibbitts S, Jamison J, Sargent A, Pollock KG, Powell N, Wilson R, McCall F, Fiander A, Soldan K.

J Clin Pathol. 2015 Feb;68(2):135-40. doi: 10.1136/jclinpath-2014-202681. Epub 2014 Nov 19.

PMID:
25410654
40.

Prevalence, risk factors, and uptake of interventions for sexually transmitted infections in Britain: findings from the National Surveys of Sexual Attitudes and Lifestyles (Natsal).

Sonnenberg P, Clifton S, Beddows S, Field N, Soldan K, Tanton C, Mercer CH, da Silva FC, Alexander S, Copas AJ, Phelps A, Erens B, Prah P, Macdowall W, Wellings K, Ison CA, Johnson AM.

Lancet. 2013 Nov 30;382(9907):1795-806. doi: 10.1016/S0140-6736(13)61947-9. Epub 2013 Nov 26.

41.

Reduction in HPV 16/18 prevalence in sexually active young women following the introduction of HPV immunisation in England.

Mesher D, Soldan K, Howell-Jones R, Panwar K, Manyenga P, Jit M, Beddows S, Gill ON.

Vaccine. 2013 Dec 17;32(1):26-32. doi: 10.1016/j.vaccine.2013.10.085. Epub 2013 Nov 6.

42.

Declining genital Warts in young women in england associated with HPV 16/18 vaccination: an ecological study.

Howell-Jones R, Soldan K, Wetten S, Mesher D, Williams T, Gill ON, Hughes G.

J Infect Dis. 2013 Nov 1;208(9):1397-403. doi: 10.1093/infdis/jit361.

43.

C. trachomatis Pgp3 antibody prevalence in young women in England, 1993-2010.

Horner P, Soldan K, Vieira SM, Wills GS, Woodhall SC, Pebody R, Nardone A, Stanford E, McClure MO.

PLoS One. 2013 Aug 21;8(8):e72001. doi: 10.1371/journal.pone.0072001. eCollection 2013.

44.

Developing role of HPV in cervical cancer prevention.

Kitchener HC, Denton K, Soldan K, Crosbie EJ.

BMJ. 2013 Aug 7;347:f4781. doi: 10.1136/bmj.f4781. Review. No abstract available. Erratum in: BMJ. 2013;347:f5207.

PMID:
23926316
45.

Risk of pelvic inflammatory disease following Chlamydia trachomatis infection: analysis of prospective studies with a multistate model.

Price MJ, Ades AE, De Angelis D, Welton NJ, Macleod J, Soldan K, Simms I, Turner K, Horner PJ.

Am J Epidemiol. 2013 Aug 1;178(3):484-92. doi: 10.1093/aje/kws583. Epub 2013 Jun 27.

46.

A randomized, observer-blinded immunogenicity trial of Cervarix(®) and Gardasil(®) Human Papillomavirus vaccines in 12-15 year old girls.

Draper E, Bissett SL, Howell-Jones R, Waight P, Soldan K, Jit M, Andrews N, Miller E, Beddows S.

PLoS One. 2013 May 1;8(5):e61825. doi: 10.1371/journal.pone.0061825. Print 2013.

47.

Opportunistic or population register based programmes for chlamydia screening?

Bone A, Soldan K, Woodhall S, Clarke J, Gill ON.

BMJ. 2012 Sep 4;345:e5887. doi: 10.1136/bmj.e5887. No abstract available.

PMID:
22951560
48.

Mixture-of-exponentials models to explain heterogeneity in studies of the duration of Chlamydia trachomatis infection.

Price MJ, Ades AE, Angelis DD, Welton NJ, Macleod J, Soldan K, Turner K, Simms I, Horner PJ.

Stat Med. 2013 Apr 30;32(9):1547-60. doi: 10.1002/sim.5603. Epub 2012 Sep 5.

PMID:
22949217
49.

Repeat genital Chlamydia trachomatis testing rates in young adults in England, 2010.

Woodhall SC, Atkins JL, Soldan K, Hughes G, Bone A, Gill ON.

Sex Transm Infect. 2013 Feb;89(1):51-6. doi: 10.1136/sextrans-2012-050490. Epub 2012 Sep 1.

PMID:
22941864
50.

Frequency and risk factors for prevalent, incident, and persistent genital carcinogenic human papillomavirus infection in sexually active women: community based cohort study.

Oakeshott P, Aghaizu A, Reid F, Howell-Jones R, Hay PE, Sadiq ST, Lacey CJ, Beddows S, Soldan K.

BMJ. 2012 Jun 22;344:e4168. doi: 10.1136/bmj.e4168.

Supplemental Content

Loading ...
Support Center